Cenobamate Drug Asset Due Diligence Report 2026

This Cenobamate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Cenobamate can convert its Small molecule drug profile and GABAA receptor x VGSCs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cenobamate (query alias: cenobamate)
Modality / target	Small molecule drug; GABAA receptor x VGSCs; GABAA receptor modulators, Voltage-gated sodium channels blockers
Highest global status	Approved
Originator	SK Biopharmaceuticals Co., Ltd.
Active developers	SK Life Science, Inc., Ono Pharmaceutical Co., Ltd., Angelini Pharma, Inc.

The MCP disease footprint includes Epilepsy, Seizures, Epilepsies, Partial. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07594158	Phase 3	Recruiting	20	Adverse events and adverse drug reactions
CTR20261958	Not Applicable	进行中（招募完成）	30	Not disclosed
CTR20262149	Not Applicable	进行中（尚未招募）	28	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population

Phase 3; n=519; evaluation: Positive. Reported fields: TEAE = The most common cenobamate-related treatment-emergent adverse events (≥20 %) were dizziness and somnolence. ; TEAE = The most common cenobamate-related treatment-emergent adverse events (≥20 %) were dizziness and somnolence. ; TEAE = The most common cenobamate-related treatment-emergent adverse events (≥20 %) were dizziness and somnolence.

SK biopharm’s Xcopri clears phase 3 in generalized seizures, setting up FDA filing

Phase 3; n=169; evaluation: Positive. Reported fields: seizure frequency = 39.6 % Met; seizure frequency = 71.9 % Met

Angelini Pharma Presents Data Demonstrating Benefits of Cenobamate▼ for Adults Living with Uncontrolled Epilepsy

Phase 3; n=129; evaluation: Positive. Reported fields: CI(1-year) = 71 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cenobamate addresses Epilepsy, Seizures, Epilepsies, Partial. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 8 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-06-10	Dong-A ST Licenses Out Epilepsy Drug Cenobamate for Australia, New Zealand	Approved	Financial terms not disclosed
2023-08-18	Hikma and SK Biopharmaceuticals enter a strategic partnership for the Middle East and North Africa	Approved	Financial terms not disclosed
2022-07-14	Eurofarma enters into partnership with SK Biopharmaceuticals to develop and market Cenobamate, a treatment for epilepsy, in 17 Latin American countries, including Brazil and Mexico.	Approved	US$15.0M upfront; US$47.0M milestones; US$62.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Process for the preparation of cenobamate annd intermediates thereof”. The milestone feed surfaced a patent-application signal described as “Process for the preparation of cenobamate and intermediates thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO